- Home
- BGH vs STRO Comparison
BGH vs STRO Comparison
Compare BGH & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGH | STRO |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 85.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BGH | STRO |
|---|---|---|
| Price | $15.14 | $10.48 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $18.29 |
| AVG Volume (30 Days) | 61.5K | ★ 121.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,646,000.00 |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.92 | $5.23 |
| 52 Week High | $14.50 | $21.50 |
Technical Indicators
Market Signals| Indicator | BGH | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 79.98 |
| Support Level | $15.08 | $8.49 |
| Resistance Level | $15.27 | $10.10 |
| Average True Range (ATR) | 0.13 | 1.02 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 52.78 | 81.73 |
Price Performance
Historical ComparisonAbout BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.